1. Home
  2. DTSQ vs TLSA Comparison

DTSQ vs TLSA Comparison

Compare DTSQ & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DTSQ
  • TLSA
  • Stock Information
  • Founded
  • DTSQ 2022
  • TLSA 2013
  • Country
  • DTSQ United States
  • TLSA United Kingdom
  • Employees
  • DTSQ N/A
  • TLSA N/A
  • Industry
  • DTSQ
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DTSQ
  • TLSA Health Care
  • Exchange
  • DTSQ NYSE
  • TLSA Nasdaq
  • Market Cap
  • DTSQ 91.7M
  • TLSA 187.0M
  • IPO Year
  • DTSQ 2024
  • TLSA 2000
  • Fundamental
  • Price
  • DTSQ N/A
  • TLSA $1.50
  • Analyst Decision
  • DTSQ
  • TLSA
  • Analyst Count
  • DTSQ 0
  • TLSA 0
  • Target Price
  • DTSQ N/A
  • TLSA N/A
  • AVG Volume (30 Days)
  • DTSQ 353.0
  • TLSA 260.9K
  • Earning Date
  • DTSQ 01-01-0001
  • TLSA 07-15-2025
  • Dividend Yield
  • DTSQ N/A
  • TLSA N/A
  • EPS Growth
  • DTSQ N/A
  • TLSA N/A
  • EPS
  • DTSQ 0.28
  • TLSA N/A
  • Revenue
  • DTSQ N/A
  • TLSA N/A
  • Revenue This Year
  • DTSQ N/A
  • TLSA N/A
  • Revenue Next Year
  • DTSQ N/A
  • TLSA N/A
  • P/E Ratio
  • DTSQ $37.05
  • TLSA N/A
  • Revenue Growth
  • DTSQ N/A
  • TLSA N/A
  • 52 Week Low
  • DTSQ $9.96
  • TLSA $0.63
  • 52 Week High
  • DTSQ $10.47
  • TLSA $1.91
  • Technical
  • Relative Strength Index (RSI)
  • DTSQ N/A
  • TLSA 48.99
  • Support Level
  • DTSQ N/A
  • TLSA $1.53
  • Resistance Level
  • DTSQ N/A
  • TLSA $1.81
  • Average True Range (ATR)
  • DTSQ 0.00
  • TLSA 0.11
  • MACD
  • DTSQ 0.00
  • TLSA -0.01
  • Stochastic Oscillator
  • DTSQ 0.00
  • TLSA 11.76

About DTSQ DT CLOUD STAR ACQUISITION CORP

DT Cloud Star Acquisition Corp is a blank check company.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: